On the fly News and insights, exclusive to thefly.com

INO

Inovio

$9.13 /

-0.02 (-0.22%)

08:15
04/23/21
04/23
08:15
04/23/21
08:15

Inovio sinks after Department of Defense stops vaccine trial funding

Shares of Inovio are sinking after the Department of Defense decided to stop funding the company's Covid-19 vaccine trial in the U.S. The Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense told Inovio that it will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed Inovio: "The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products." The decision does not impact other work that Inovio does with the U.S. government and is neither a result of the partial clinical hold nor a reflection of the data generated to date for INO-4800 vaccine, the company said in a statement. The company is planning for a predominantly outside the U.S. Phase 3 trial based on upcoming evaluation of Phase 2 safety and immunogenicity data. Inovio shares in premarket trading are down 23%, or $2.13, to $7.00.

  • 13

    May

  • 21

    Jan

INO Inovio
$9.13 /

-0.02 (-0.22%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.